Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
AKBA

AKBA - Akebia Therapeutics Inc Stock Price, Fair Value and News

1.35USD-0.01 (-0.74%)Market Closed

Market Summary

AKBA
USD1.35-0.01
Market Closed
-0.74%

AKBA Stock Price

View Fullscreen

AKBA RSI Chart

AKBA Valuation

Market Cap

283.0M

Price/Earnings (Trailing)

-6.58

Price/Sales (Trailing)

1.66

EV/EBITDA

-6.41

Price/Free Cashflow

-11.19

AKBA Price/Sales (Trailing)

AKBA Profitability

Operating Margin

61.63%

EBT Margin

-30.39%

Return on Equity

157.87%

Return on Assets

-19.09%

Free Cashflow Yield

-8.93%

AKBA Fundamentals

AKBA Revenue

Revenue (TTM)

170.9M

Rev. Growth (Yr)

-18.49%

Rev. Growth (Qtr)

-41.98%

AKBA Earnings

Earnings (TTM)

-43.0M

Earnings Growth (Yr)

33.08%

Earnings Growth (Qtr)

-3.0K%

Breaking Down AKBA Revenue

Last 7 days

7.1%

Last 30 days

33.7%

Last 90 days

-0.7%

Trailing 12 Months

9.8%

How does AKBA drawdown profile look like?

AKBA Financial Health

Current Ratio

1.7

Debt/Equity

-1.11

Debt/Cashflow

-0.84

AKBA Investor Care

Shares Dilution (1Y)

12.73%

Diluted EPS (TTM)

-0.22

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024170.9M000
2023271.0M0186.3M193.8M
2022221.0M294.9M294.8M292.7M
2021236.0M198.7M232.5M211.7M
2020350.8M340.2M263.2M272.1M
2019234.5M286.5M325.3M335.0M
2018203.0M223.3M235.2M207.7M
201722.5M51.0M92.2M178.0M
20160001.8M
2015612.2K525.2K410.2K0
2014962.4K875.0K787.6K700.2K
2013001.5M1.0M
20120002.0M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Akebia Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 28, 2024
ostrowski erik
acquired
-
-
350,000
svp, cfo, cbo & treasurer
Jun 06, 2024
gilman steven c
acquired
-
-
30,000
-
Jun 06, 2024
frieson ron
acquired
-
-
30,000
-
Jun 06, 2024
adams adrian
acquired
-
-
30,000
-
Jun 06, 2024
wolf myles
acquired
-
-
30,000
-
Jun 06, 2024
rogers michael w
acquired
-
-
30,000
-
Jun 06, 2024
smith cynthia
acquired
-
-
30,000
-
Jun 06, 2024
zumwalt leanne m
acquired
-
-
30,000
-
May 13, 2024
hadas nicole r.
sold
-15,140
1.26
-12,016
svp, chief legal officer

1–10 of 50

Which funds bought or sold AKBA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 19, 2024
RAYMOND JAMES & ASSOCIATES
added
24.25
-23,203
52,264
-%
Jul 18, 2024
Assenagon Asset Management S.A.
reduced
-73.23
-1,230,700
215,880
-%
Jul 18, 2024
Independent Wealth Network Inc.
unchanged
-
-9,722
12,243
0.01%
Jul 18, 2024
EAGLE WEALTH STRATEGIES LLC
unchanged
-
-7,320
12,240
0.01%
Jul 17, 2024
James J. Burns & Company, LLC
unchanged
-
-9,000
16,000
-%
Jul 16, 2024
Ameliora Wealth Management Ltd.
unchanged
-
-4,548
5,727
-%
Jul 16, 2024
GPS Wealth Strategies Group, LLC
new
-
3,698
3,698
-%
Jul 15, 2024
SAPIENT CAPITAL LLC
unchanged
-
-162,000
204,000
-%
Jul 12, 2024
Hexagon Capital Partners LLC
sold off
-100
-340
-
-%
Jul 12, 2024
Compass Ion Advisors, LLC
unchanged
-
-
45,924
0.01%

1–10 of 40

Are Funds Buying or Selling AKBA?

Are funds buying AKBA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AKBA
No. of Funds

Unveiling Akebia Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
4.04%
7,607,472
SC 13G/A
Feb 09, 2024
satter muneer a
8.6%
16,205,119
SC 13G/A
Feb 10, 2023
satter muneer a
8.2%
15,090,119
SC 13G/A
Feb 09, 2023
vanguard group inc
6.11%
11,238,870
SC 13G/A
Jan 20, 2023
state street corp
0.31%
571,936
SC 13G/A
Dec 19, 2022
satter muneer a
7.5%
13,864,330
SC 13G
Jul 08, 2022
blackrock inc.
2.4%
4,340,026
SC 13G
Jun 09, 2022
vanguard group inc
10.00%
18,359,420
SC 13G/A
Feb 10, 2022
state street corp
6.71%
11,743,461
SC 13G/A
Feb 09, 2022
vanguard group inc
7.56%
13,235,669
SC 13G/A

Recent SEC filings of Akebia Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jul 11, 2024
8-K
Current Report
Jul 02, 2024
4
Insider Trading
Jun 26, 2024
3
Insider Trading
Jun 24, 2024
8-K
Current Report
Jun 10, 2024
8-K
Current Report
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading
Jun 10, 2024
4
Insider Trading

Peers (Alternatives to Akebia Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.4B
6.8B
-9.08% -2.89%
-7.78
6.94
-64.45% -224.75%
30.1B
2.0B
54.57% 18.06%
-90.59
15.02
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.0B
2.5B
-0.07% -3.94%
77.72
6.46
13.74% 186.89%
14.8B
3.8B
7.23% 2.92%
19.84
3.93
8.58% 129.81%
MID-CAP
4.9B
107.9M
-5.14% -24.06%
-8.96
48.09
54.84% -28.31%
4.6B
524.1M
-5.19% 10.95%
-11.05
8.8
394.93% 39.61%
4.0B
251.0M
11.60% 13.99%
-13.6
16.05
73.58% -86.73%
3.5B
240.7M
20.06% -18.70%
-7.43
12.77
-1.03% -213.92%
2.9B
813.8M
19.30% -43.25%
-1.7K
3.6
56.43% 98.83%
1.9B
996.6M
0.36% 71.71%
-4.87
1.95
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
13.16% 23.83%
30.73
4.86
60.38% -34.49%
618.2M
881.7K
32.05% 709.09%
-18.31
481.06
-77.61% 33.36%
260.1M
4.2M
17.29% 54.94%
-2.08
62.54
-66.30% 48.24%
18.8M
2.1M
-4.39% -80.54%
-0.81
7.61
-13.45% 69.54%

Akebia Therapeutics Inc News

Latest updates
American Banking and Market News18 Jul 202406:00 am
Seeking Alpha11 Jul 202407:00 am

Akebia Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-42.0%32,607,00056,196,00042,046,00040,005,00055,547,00048,714,000126,759,00061,699,00057,677,00048,756,00052,913,00052,304,00078,530,00015,000,00090,142,00088,478,00069,555,00091,977,000100,803,00072,666,00059,850,000
Cost Of Revenue-37.8%11,605,00018,666,00018,009,00020,189,000-3,043,00038,281,00018,600,00031,344,00047,626,50015,944,00052,495,00034,606,00063,234,00030,345,000174,616,00027,713,00038,147,00038,263,00037,669,00031,257,0007,768,000
Operating Expenses-0.6%35,938,00036,156,50037,073,00045,413,00064,199,50060,838,00073,690,00088,848,00075,389,50087,698,00079,759,00082,634,00078,868,00087,738,00089,345,000119,890,000126,299,000109,619,000122,657,000117,378,000142,240,000
  S&GA Expenses0.0%25,438,00025,435,00022,710,00025,053,00029,908,00031,887,00032,240,00044,566,00044,804,00046,357,00041,651,00041,328,00040,463,00040,171,00035,482,00037,983,00044,918,00034,178,00036,068,00034,291,00055,121,000
  R&D Expenses-1.4%9,731,0009,865,50013,330,00019,686,00032,098,00028,028,00026,027,00043,833,00029,556,00040,471,00037,214,00040,611,00037,578,00046,857,00052,819,00081,231,00080,412,00074,512,00085,694,00082,351,00087,052,000
EBITDA Margin-13.4%-0.26-0.23-0.46-0.32-0.29-0.92-0.92-1.22-1.28-1.61-1.89----------
Income Taxes------------------1,752,000-1,277,000-845,000-2,757,000-28,338,000
Earnings Before Taxes-Infinity%-17,985,000---26,876,000---------88,384,000-59,959,000-175,751,000-60,747,000-96,235,000-55,862,000-59,015,000-75,178,000-88,392,000
EBT Margin-13.4%-0.30-0.27-0.51-0.35-0.32-0.96-0.96-1.28-1.33-1.66-1.94----------
Net Income-3033.9%-17,985,000613,000-14,489,000-26,876,000-6,070,500-54,096,00029,449,000-63,509,000-69,862,000-59,544,000-83,038,000-69,580,000-87,000,000-59,959,000-175,751,000-60,747,000-94,483,000-54,585,000-58,170,000-72,421,000-60,054,000
Net Income Margin6.0%-0.25-0.27-0.31-0.21-0.32-0.54-0.55-1.25-1.33-1.29-1.51----------
Free Cashflow-741.9%-19,432,000-2,308,000-7,167,000-17,540,000-54,679,00033,805,000-30,660,000-21,734,000-62,808,000-56,270,000-63,141,000----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-6.7%225242235254281356444530542529602612629644676745788771795824891
  Current Assets-4.4%113118110118121185242308305271330331365371391449341310299316347
    Cash Equivalents-2.2%42.0043.0047.0054.0060.0093.0014814717815220924925522917224811815012387.0063.00
  Inventory62.7%26.0016.0018.0021.0020.0022.0045.0040.0041.0037.0034.0038.0045.0061.0088.00105112116116122115
  Net PPE-10.0%3.004.004.004.005.005.006.006.006.007.007.008.008.009.009.009.0010.0010.0013.0011.0010.00
  Goodwill-0.1%59.0059.0059.0059.0059.0059.0059.0059.0059.0059.0055.0055.0055.0055.0055.0055.0055.0055.0055.0055.0055.00
Liabilities-7.2%253272274281300351436471519455465437415397358375391376328304324
  Current Liabilities-33.4%66.0010080.0092.0088.00130193237258261189166173187181196214208223186203
  Long Term Debt75.4%30.0017.0035.0018.0026.0034.00----97.0097.0097.0096.0077.0076.0076.0076.00---
    LT Debt, Current-100.0%-18.008.0024.0024.0032.0066.0098.0098.0098.00-----------
    LT Debt, Non Current75.4%30.0017.0035.0018.0026.0034.00----97.0097.0097.0096.0077.0076.0076.0076.00---
Shareholder's Equity10.9%-27.26-30.58---19.125.008.0059.0023.0074.00137175214244318370396393468519566
  Retained Earnings-1.1%-1,626-1,608-1,609-1,595-1,583-1,557-1,550-1,496-1,526-1,462-1,389-1,330-1,247-1,177-1,090-1,030-854-794-699-644-586
  Additional Paid-In Capital1.4%1,6001,5781,5701,5681,5651,5621,5591,5561,5491,5371,5271,5051,4611,4251,4081,4011,2511,1891,1671,1641,153
Shares Outstanding7.6%209195188188185184184184180177174161---------
Float----170---64.00---632---1,914---566-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-741.9%-19,432-2,308-7,1673,629-17,538-54,67933,805-30,660-21,620-62,808-56,270-63,141-70,746-30,782-27,23737,220-89,589-92,13510,989-38,366-137,929
  Share Based Compensation55.2%2,3601,5211,8003,5002,4893,0413,3556,9174,5364,6365,5936,5145,9926,0886,5926,8644,9164,9342,6132,2842,094
Cashflow From Investing----------114--20,00019,94159,683-49,937-49,99524522,28024,39054,033110,473
Cashflow From Financing1532.2%18,475-1,29050.00-8,000-15,966-1.00-32,937-9.0047,5455,40316,48237,36974,47730,5111,054142,80757,34894,4181958,804-14,447
  Buy Backs--------------------426-
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

AKBA Income Statement

2024-03-31
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues  
Total revenues$ 32,607$ 40,005
Cost of goods sold  
Cost of product and other revenue2,59411,178
Amortization of intangible asset9,0119,011
Total cost of goods sold11,60520,189
Operating expenses:  
Research and development9,73119,686
Selling, general and administrative25,43825,053
License711568
Restructuring58106
Total operating expenses35,93845,413
Loss from operations(14,936)(25,597)
Other income (expense)  
Interest expense(2,498)(1,561)
Other income95282
Change in fair value of warrant liability(129)0
Loss on extinguishment of debt(517)0
Net loss before income taxes(17,985)(26,876)
Net (loss) income, basic(17,985)(26,876)
Net (loss) income, diluted(17,985)(26,876)
Comprehensive loss$ (17,985)$ (26,876)
Net loss per share:  
Basic (in dollars per share)$ (0.09)$ (0.15)
Diluted (in dollars per share)$ (0.09)$ (0.15)
Weighted average common shares outstanding:  
Basic (in shares)204,955,151184,768,983
Diluted (in shares)204,955,151184,768,983
Product revenue, net  
Revenues  
Total revenues$ 31,009$ 34,706
License, collaboration and other revenue  
Revenues  
Total revenues$ 1,598$ 5,299

AKBA Balance Sheet

2024-03-31
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 41,961$ 42,925
Inventories25,53215,691
Accounts receivable, net26,62039,290
Prepaid expenses and other current assets18,83120,243
Total current assets112,944118,149
Property and equipment, net3,2653,629
Operating right-of-use assets11,39912,416
Intangible asset, net27,03236,042
Goodwill59,04459,044
Other long-term assets11,79312,423
Total assets225,477241,703
Current liabilities:  
Accounts payable11,88214,635
Accrued expenses and other current liabilities53,91067,735
Short-term deferred revenue6950
Current portion of long-term debt017,500
Total current liabilities66,48799,870
Deferred revenue, net of current portion43,29643,296
Long-term operating lease liabilities7,6368,947
Long-term debt, net30,14517,183
Liability related to sale of future royalties53,49854,013
Refund liability to customer39,92740,093
Warrant liability4,9750
Other long-term liabilities6,7718,885
Total liabilities252,735272,287
Commitments and contingencies (Note 10)
Stockholders' deficit:  
Preferred stock $0.00001 par value, 25,000,000 shares authorized; no shares issued and    outstanding at March 31, 2024 and December 31, 202300
Common stock $0.00001 par value; 350,000,000 shares authorized at March 31, 2024 and December 31, 2023; 209,454,149 and 194,582,539 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively22
Additional paid-in capital1,599,6691,578,358
Accumulated other comprehensive income66
Accumulated deficit(1,626,935)(1,608,950)
Total stockholders' deficit(27,258)(30,584)
Total liabilities and stockholders' deficit$ 225,477$ 241,703
AKBA
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEakebia.com
 INDUSTRYBiotechnology
 EMPLOYEES204

Akebia Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Akebia Therapeutics Inc? What does AKBA stand for in stocks?

AKBA is the stock ticker symbol of Akebia Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Akebia Therapeutics Inc (AKBA)?

As of Fri Jul 19 2024, market cap of Akebia Therapeutics Inc is 282.96 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AKBA stock?

You can check AKBA's fair value in chart for subscribers.

What is the fair value of AKBA stock?

You can check AKBA's fair value in chart for subscribers. The fair value of Akebia Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Akebia Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AKBA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Akebia Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AKBA is over valued or under valued. Whether Akebia Therapeutics Inc is cheap or expensive depends on the assumptions which impact Akebia Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AKBA.

What is Akebia Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, AKBA's PE ratio (Price to Earnings) is -6.58 and Price to Sales (PS) ratio is 1.66. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AKBA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Akebia Therapeutics Inc's stock?

In the past 10 years, Akebia Therapeutics Inc has provided -0.248 (multiply by 100 for percentage) rate of return.